LivaNova - Page title

Press Releases

Apr 05, 2019

LivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results

LONDON --(BUSINESS WIRE)--Apr. 5, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019 . Preliminary First Quarter 2019 Results The Company expects worldwide sales from continuing...Read More
Apr 01, 2019

LivaNova to Present at the Needham Healthcare Conference

LONDON --(BUSINESS WIRE)--Apr. 1, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer of LivaNova , will present at the Needham Healthcare Conference on Tuesday, April 9 in New York at 2:10 p.m....Read More
Mar 29, 2019

LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device

LONDON --(BUSINESS WIRE)--Mar. 29, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device....Read More
Mar 18, 2019

LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer

LONDON --(BUSINESS WIRE)--Mar. 18, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team...Read More
Mar 15, 2019

LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session

LONDON --(BUSINESS WIRE)--Mar. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology...Read More
Feb 27, 2019

LivaNova Reports Fourth Quarter and Full-Year 2018 Results

LONDON --(BUSINESS WIRE)--Feb. 27, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018 . For the fourth quarter of 2018, worldwide sales were $297.0 million , an increase of 6.7...Read More
Feb 25, 2019

LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform

New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions LONDON --(BUSINESS WIRE)--Feb. 25, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve...Read More
Feb 21, 2019

LivaNova’s Perceval Sutureless Aortic Heart Valve Receives National Reimbursement in Japan to Treat Patients with Aortic Valve Disease

LONDON --(BUSINESS WIRE)--Feb. 21, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval ® sutureless aortic heart valve to treat aortic valve...Read More
Feb 15, 2019

LivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression

Company plans to submit clinical study protocol for CMS consideration LONDON --(BUSINESS WIRE)--Feb. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage...Read More
Jan 28, 2019

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2018 Results

LONDON --(BUSINESS WIRE)--Jan. 28, 2019-- LivaNova PLC  (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on  Wednesday, Feb. 27, 2019 at  1 p.m. London time ( 8 a.m. Eastern Standard Time )....Read More
Jan 17, 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON --(BUSINESS WIRE)--Jan. 17, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies...Read More